2025年ESMO肉瘤和罕见癌症大会

◆ 会议时间：2025年3月20-22日
◆ 会议地点：瑞士 卢加诺

◆ 会议简介：

2025年ESMO肉瘤和罕见癌症大会将于2025年3月20-22日在瑞士卢加诺举行，会议由欧洲肿瘤内科学会(ESMO)主办。会议将深入探讨罕见实体瘤的诊断、治疗方式、生物学和分子分型方面的最新进展，为与会者提供该专业领域快速发展的全面概述。无论您是经验丰富的肿瘤学家、专业的研究人员、医疗保健专业人士、制药行业领导者还是患者权益倡导者，本次活动都可以为致力于推进肉瘤和罕见癌症患者的护理和改善治疗结果的每个人提供一些帮助。

欧洲肿瘤内科学会（ESMO）成立于1975年，是全球领先的肿瘤内科学专业组织。ESMO是肿瘤学教育和信息的参考学会，现在全球160多个国家和地区拥有超过25,000余名会员；ESMO致力于通过宣促进多学科的癌症护理，支持肿瘤学家的专业发展以及在全球倡导可持续的癌症护理，尽而为癌症患者提供最佳的护理。未经许可禁止复制摘录转载本站任何内容-国际医学会议网（lingyuint.com）。

ESMO Sarcoma & Rare Cancers Congress 2025

Date:
20-22 March 2024

Venue:
Lugano, Switzerland

The ESMO Sarcoma and Rare Cancers Congress 2025 promises to be an excellent platform for the exchange of cutting-edge research, innovative therapeutic approaches, and collaborative discussions aimed at advancing the field of oncology.

Mark your calendars for 20 – 22 March 2025, as we converge in the picturesque city of Lugano, Switzerland, renowned for its scenic beauty and vibrant culture.

The ESMO Sarcoma and Rare Cancers Congress 2025 scientific and educational programme will delve into the latest developments in diagnosis, treatment modalities, biology, and molecular classification of rare solid tumours, offering attendees a comprehensive overview of the rapidly evolving landscape in this specialised area.

Whether you are a seasoned oncologist, a dedicated researcher, a healthcare professional, a pharmaceutical industry leader, or a patient advocate, this event offers something for everyone committed to advancing the care and improving outcomes of patients with sarcomas and rare cancers.

We look forward to welcoming you to Lugano, for an unforgettable experience of learning, collaboration, and discovery at the forefront of oncology.

Scientific Co-Chairs

• Jean-Yves Blay, Lyon, France
• Eva Tiensuu Janson, Uppsala, Sweden
• Claudia Valverde, Barcelona, Spain

以下为上届会议信息

摘要征文投稿：

Abstract submission deadlines

点此提交摘要>>>Submit Abstract>>>

• 提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations

Submission categories

• Central Nervous System (CNS)
• Digestive cancers
• Genitourinary cancers
• Gynaecological cancers
• Head and neck cancers
• Neuroendocrine and Endocrine cancers
• Public Policy and Patient Advocacy
• Research methodology
• Sarcoma
• Skin cancers and Melanomas
• Thoracic cancers
• Miscellaneous

Outcome notifications

Outcome notifications are expected to be made available to first authors and submitters by end-January 2024.

Trial in Progress abstracts

Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to the ESMO Sarcoma and Rare Cancers Congress 2024.

It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.

Presentation of accepted abstracts

The ESMO Sarcoma and Rare Cancers 2024 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities:

• Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
• Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
• Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work during Poster display session.

All accepted abstracts will be published online in the ESMO Sarcoma and Rare Cancers Congress 2024 Abstract Book, a supplement to ESMO Open.

Publication schedule of accepted abstracts

Abstracts accepted for presentation during the ESMO Sarcoma and Rare Cancers Congress 2024 will be released online according to a schedule which will be available on the ESMO website in due course.

ESMO Merit Travel Grants

A limited number of ESMO Merit Travel Grants to the ESMO Sarcoma and Rare Cancers Congress 2024 are available, upon application, to first authors (= presenters) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Sarcoma and Rare Cancers 2024 Scientific Committee on a competitive basis from among the accepted abstracts.

注册费：

In-person participation includes:

• Participation in the scientific and educational live sessions with the possibility to interact with the expert panel
• Onsite networking opportunity with faculty and peers
• Entry to the Poster area
• Interaction with the Industry partners in the trade exhibition
• Participation in the Industry Satellite Symposia
• Access to the Post-event resources and sessions on-demand
• Coffee breaks and lunches

Registration fees and deadlines

Individual registration will remain open for the duration of the congress. The ESMO Congress Secretariat must receive one completed registration per participant and the corresponding payment in EUR by the given deadlines.

ESMO membership must be active seven (7) days prior to the registration deadline for the reduced member registration fee to be applied. Please visit the membership page to check eligibility criteria, benefits, and to complete the membership application.

*Applicable to ESMO members from developing countries only. At the time of application, developing countries are defined by ESMO according to the World Bank classification of low, lower-middle and upper-middle countries based on the Gross National Income (GNI) per capita. Download the PDF outlining which countries are eligible for the discounted registration fees.
**ESMO Members must be under 40 and in training to qualify for this fee

Confirmation

By end-February 2024 delegates will receive the registration confirmation email and instructions on how to access the ESMO Sarcoma and Rare Cancers Congress 2024.